A Randomized, Open-Label, Parallel-Design Trial. Glycemia Optimization Treatment: Safety of Glucose Control Using Dosing Algorithms With Lantus (Insulin Glargine [rDNA Origin[) in Adult Individuals With Type 2 Diabetes.
Phase of Trial: Phase IV
Latest Information Update: 22 Jul 2009
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 22 Jul 2009 Planned end date changed from Feb 2005 to Mar 2005 as reported by ClinicalTrials.gov.
- 22 Jul 2009 Actual patient number (5062) added as reported by ClinicalTrials.gov.